Zoetis Inc. (ZTS) Sees Mixed Analyst Sentiment as Targets Are Trimmed

Zoetis Inc. (NYSE:ZTS) is among the most profitable healthcare stocks to buy. On January 15, Jonathan Block, an analyst at Stifel Nicolaus, reaffirmed a Hold rating and $130 price target on Zoetis Inc. (NYSE:ZTS). As the lowest 1-year price target among Wall Street analysts, the firm’s target translates to an upside potential of 4.91%.

Later, on January 22, Piper Sandler downgraded Zoetis Inc. (NYSE:ZTS) from Overweight to Neutral, while trimming the price target to $135, down from $190. Despite being bullish on the company’s long-term portfolio, the firm is not yet comfortable with projections over the upcoming years until more of the company’s innovations reach the market. That said, the company “is in an innovation air pocket that could last one to two years,” according to the analyst.

Morgan Stanley also cut the price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and maintained an Overweight rating on December 18. The firm believes there is an “attractive backdrop for alpha-generation opportunities” for healthcare companies in 2026. On the other hand, managed care stocks have performed weakly in 2025 and are experiencing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst concluded.

​Zoetis Inc. (NYSE:ZTS) is a New Jersey-based provider of various health products, including animal health medicines, vaccines, biodevices, and genetic tests. Incepted in 1950, the company is dedicated to becoming the most valuable animal health company.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.